Endogenics · Mechanistic disease simulation
The mechanistic intelligence layer for disease biology.
Turn fragmented disease data into causal answers for high-stakes program decisions.
Core solutions
The four program decisions
The shift · The causal divide
Correlation finds patterns. Causality discovers medicines.
Generative AI has automated molecular design, but biology remains the ultimate bottleneck. Today, more capital than ever is chasing fewer novel targets,1,2 because traditional tools match patterns without understanding mechanisms.
Statistical machine learning excels where data is abundant, but foundational disease biology is inherently sparse and dynamic. Black-box correlations fail in the clinic because they cannot explain why a disease progresses or how a pathway compensates.
BioFi bridges this divide with dynamic biological intelligence—simulating how complex human systems evolve in continuous time to turn uncertain hypotheses into mechanisms you can test.
The platform & technology
Endogenics™
Endogenics pairs agentic workflows with specialized dynamic simulation. Proprietary pipelines translate patient multi-omics datasets into structured, interconnected disease systems—modeling how human biology behaves, evolves, and responds to intervention in continuous time.
The compounding platform advantage
Asset-Light Agility
Operates directly on existing patient and multi-omics data, augmenting and compounding the evidence you already have.
Continuous Asset Intelligence
Partners own their calibrated disease models that improve with every simulation cycle and additional evidence that is fed into the platform and generated from it.
Our team
Diverse in experience, aligned in vision

Background
Background in Biotechnology and Medical Informatics; +10 years experience in the Life Science sector including AstraZeneca, managing cross-functional projects across the drug R&D value chain.
Thomas Nirnberger
Co-founder & Chief Executive Officer

Background
Engineer and MBA, former treasurer and inventor at Hewlett-Packard and CEO at Crowley-Davis Research. Inventor of cutting-edge technologies, including algorithms powering the HP-80 and HP-12c pocket calculators
Bill Crowley
Co-founder & Chairman

Background
Engineer and theoretical physicist with a distinguished academic career at the Max Planck Institute for Astronomy and University of Zürich. Expert in high performance computing and software engineering. Previously simulated the formation of planets, an invaluable experience he now applies to biology.
Clement Surville
Director Computational Science

Background
Industrial research and development technician turned data scientist and bioinformatician. Broad understanding of the biopharmaceutical industry with specialist skills in computational biology.
Kristina Djordjevic
Director Bioinformatics

Background
Bioengineer from the EPFL turned full stack software developer. Extensive experience in web application and infrastructure development.
Léonard Gable
Director Software Engineering

Background
CEO of LLAAMA. +20 years of software engineering experience in the pharmaceutical industry (Roche, Actelion, Idorsia). Experience in building high performing software development teams. Distributed systems enthusiast.
Bernard Deffarges
Technical Advisor
Bring a program decision. Leave with a causal answer.
Bring us a live program questionOur mission
No drug program should fail for a biological truth we could have known before the trial.
Behind every clinical trial is a patient waiting for a life-changing answer. Developing novel medicines is one of humanity's toughest scientific challenges, where unexpected biological complexities can derail even the most dedicated R&D efforts. BioFi exists to give drug development teams clarity where it matters most. By uncovering the true causal drivers of disease before trials begin, we help biopharma match the right target to the right patient population from the start, ensuring every program advances with conviction and reaches the people who need it.